A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies

Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs INCB 54828 (Primary) ; Cisplatin; Docetaxel; Gemcitabine; Pembrolizumab; Trastuzumab
  • Indications Multiple myeloma; Myeloproliferative disorders; Solid tumours
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 17 Jul 2017 Planned number of patients changed from 250 to 280.
    • 17 Jul 2017 Planned End Date changed from 1 Feb 2018 to 1 Dec 2018.
    • 17 Jul 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top